TRU-015: Additional Phase IIb data

Data from an ongoing, open-label extension of a Phase IIb trial in 226 patients who were retreated for a second time with 800 mg TRU-015 had ACR 20, 50 and 70 response rates of 72%, 39%, and 21%, resp...